The E5 protein of human papillomavirus type 16 perturbs MHC class II antigen maturation in human foreskin keratinocytes treated with interferon-gamma.

[1]  T. Hofmann,et al.  The Human Papillomavirus Oncoprotein E7 Attenuates NF-κB Activation by Targeting the IκB Kinase Complex* , 2002, The Journal of Biological Chemistry.

[2]  Anthony D. Kelleher,et al.  Characterization of CD4+ CTLs Ex Vivo1 , 2002, The Journal of Immunology.

[3]  D. Spandau,et al.  E5 Protein of Human Papillomavirus Type 16 Protects Human Foreskin Keratinocytes from UV B-Irradiation-Induced Apoptosis , 2002, Journal of Virology.

[4]  E. Mellins,et al.  Rheumatoid Arthritis (RA)-Associated HLA-DR Alleles Form Less Stable Complexes with Class II-Associated Invariant Chain Peptide Than Non-RA-Associated HLA-DR Alleles1 , 2001, The Journal of Immunology.

[5]  U. Ritz,et al.  Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. , 2001, International journal of oncology.

[6]  B. Steinberg,et al.  Interaction of human papillomavirus type 11 E7 protein with TAP-1 results in the reduction of ATP-dependent peptide transport. , 2001, Clinical immunology.

[7]  U. Gyllensten,et al.  HLA class II alleles associated with infection by HPV16 in cervical cancer in situ , 2001, International journal of cancer.

[8]  D. Yoon,et al.  Both E6 and E7 Oncoproteins of Human Papillomavirus 16 Inhibit IL-18-Induced IFN-γ Production in Human Peripheral Blood Mononuclear and NK Cells1 , 2001, The Journal of Immunology.

[9]  B. Deurs,et al.  The HPV16 E5 oncogene inhibits endocytic trafficking , 2000, Oncogene.

[10]  G. Blair,et al.  Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins , 2000, Oncogene.

[11]  S. Tyring.  Human papillomavirus infections: epidemiology, pathogenesis, and host immune response. , 2000, Journal of the American Academy of Dermatology.

[12]  P. Stern,et al.  Multiple mechanisms underlie HLA dysregulation in cervical cancer. , 2000, Tissue antigens.

[13]  B. Steinberg,et al.  Altered Expression of TAP-1 and Major Histocompatibility Complex Class I in Laryngeal Papillomatosis: Correlation of TAP-1 with Disease , 2000, Clinical Diagnostic Laboratory Immunology.

[14]  O. Rudenko,et al.  The HPV-16 E5 oncogene and bafilomycin A(1) influence cell motility. , 1999, Biochimica et biophysica acta.

[15]  G. Fleuren,et al.  HLA and susceptibility to cervical neoplasia. , 1999, Human immunology.

[16]  A. Singer,et al.  The antigen‐presenting environment in normal and human papillomavirus (HPV)‐related premalignant cervical epithelium , 1999, Clinical and experimental immunology.

[17]  L. Kalish,et al.  Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. , 1999, Journal of the National Cancer Institute.

[18]  G. Fleuren,et al.  HLA class I phenotype and genotype alterations in cervical carcinomas and derivative cell lines. , 1998, Tissue antigens.

[19]  E. Auvinen,et al.  The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT. , 1998, Experimental cell research.

[20]  G. Girolomoni,et al.  Interferon-γ-stimulated human keratinocytes express the genes necessary for the production of peptide-loaded MHC class II molecules , 1998 .

[21]  H. Chapman,et al.  Endosomal proteolysis and MHC class II function. , 1998, Current opinion in immunology.

[22]  E. Auvinen,et al.  Enhancement of EGF- and PMA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein , 1997, Oncogene.

[23]  J. Bornstein,et al.  Interferon‐β and ‐γ, but not tumor necrosis factor‐α, demonstrate immunoregulatory effects on carcinoma cell lines infected with human papillomavirus , 1997 .

[24]  D. McCance,et al.  The E5 gene of HPV-16 enhances keratinocyte immortalization by full-length DNA. , 1996, Virology.

[25]  H. Ploegh,et al.  Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. , 1996, Immunity.

[26]  D. DiMaio,et al.  The HPV16 E5 protein: expression, detection, and stable complex formation with transmembrane proteins in COS cells. , 1995, Virology.

[27]  J. Kartenbeck,et al.  Human papillomavirus type 16 E5 protein affects cell-cell communication in an epithelial cell line , 1995, Journal of virology.

[28]  D. McCance,et al.  The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes , 1995, Journal of virology.

[29]  F. Koning,et al.  Distribution of HLA class II molecules in epidermal Langerhans cells in situ , 1995, European journal of immunology.

[30]  H. Ploegh,et al.  How MHC class II molecules reach the endocytic pathway. , 1995, The EMBO journal.

[31]  A. Chervonsky,et al.  The requirement for DM in class II-restricted antigen presentation and SDS-stable dimer formation is allele and species dependent , 1995, The Journal of experimental medicine.

[32]  P. Cresswell,et al.  In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. , 1994, Immunity.

[33]  C. Watts,et al.  Antigen processing and class II MHC peptide-loading compartments in human B-lymphoblastoid cells , 1994, Nature.

[34]  I. Mellman,et al.  Transient accumulation of new class II MHC molecules in a novel endocytic compartment in B lymphocytes , 1994, Nature.

[35]  M. Taylor,et al.  Endosomal aspartic proteinases are required for invariant-chain processing. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Stanley,et al.  Analysis of HLA‐DR expression on keratinocytes in cervical neoplasia , 1994, International journal of cancer.

[37]  R. Schlegel,et al.  The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein , 1993, Journal of virology.

[38]  G. Loss,et al.  Invariant chain retains MHC class II molecules in the endocytic pathway. , 1993, Journal of immunology.

[39]  P. Stern,et al.  HLA class II antigen expression in human papillomavirus-associated cervical cancer. , 1992, Cancer research.

[40]  J. Neefjes,et al.  Inhibition of endosomal proteolytic activity by leupeptin blocks surface expression of MHC class II molecules and their conversion to SDS resistance alpha beta heterodimers in endosomes. , 1992, The EMBO journal.

[41]  P. Stahl,et al.  Proteolytic cleavage of ricin A chain in endosomal vesicles. Evidence for the action of endosomal proteases at both neutral and acidic pH. , 1991, The Journal of biological chemistry.

[42]  C. Scully,et al.  MHC antigen expression in human oral squamous carcinoma cell lines , 1991, The Journal of pathology.

[43]  R. Germain,et al.  A role for peptide in determining MHC class II structure , 1991, Nature.

[44]  H. Hausen.  Human papillomaviruses in the pathogenesis of anogenital cancer. , 1991 .

[45]  M. Davis,et al.  Expression of a class II major histocompatibility complex (MHC) heterodimer in a lipid-linked form with enhanced peptide/soluble MHC complex formation at low pH , 1991, The Journal of experimental medicine.

[46]  H. Geuze,et al.  Segregation of MHC class II molecules from MHC class I molecules in the Golgi complex for transport to lysosomal compartments , 1991, Nature.

[47]  P. Stern,et al.  Loss of MHC class‐I expression in cervical carcinomas , 1990, International journal of cancer.

[48]  O. Baadsgaard,et al.  The Cellular Immune Response to Human Papillomavirus Infection , 1990, International journal of dermatology.

[49]  P. Cresswell,et al.  Role for intracellular proteases in the processing and transport of class II HLA antigens. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[50]  D. Manias,et al.  Epidermodysplasia Verruciformis: A Case Associated With Primary Lymphatic Dysplasia, Depressed Cell-Mediated Immunity, and Bowen's Disease Containing Human Papillomavirus 16 DNA , 1987 .

[51]  R. Kurman,et al.  Tissue effects of and host response to human papillomavirus infection. , 1987, Obstetrics and gynecology clinics of North America.

[52]  N. Romani,et al.  HLA‐DR expression on keratinocytes is a common feature of diseased skin , 1986, The British journal of dermatology.

[53]  T. Merigan,et al.  Keratinocyte class II histocompatibility antigen expression , 1985, The British journal of dermatology.

[54]  P. Cresswell,et al.  Analysis of monoclonal antibodies reactive with human class II beta chains by two-dimensional electrophoresis and Western blotting. , 1984, Human immunology.

[55]  G. Hämmerling,et al.  Structure of Ia antigens: identification of dimeric complexes formed by the invariant chain. , 1982, Journal of immunology.

[56]  P. Cresswell.  Human B cell alloantigens: separation from other membrane molecules by affinity chromatography , 1977 .

[57]  P. Peterson,et al.  Isolation and characterization of human B cell alloantigens. , 1976, Journal of immunology.

[58]  H. Green,et al.  Seria cultivation of strains of human epidemal keratinocytes: the formation keratinizin colonies from single cell is , 1975, Cell.

[59]  R. Tindle.  Immune evasion in human papillomavirus-associated cervical cancer , 2002, Nature Reviews Cancer.

[60]  H. Ploegh,et al.  How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. , 1995, Annual review of cell and developmental biology.

[61]  G. McFadden,et al.  How DNA viruses perturb functional MHC expression to alter immune recognition. , 1994, Advances in cancer research.

[62]  P. Cresswell,et al.  Assembly, transport, and function of MHC class II molecules. , 1994, Annual review of immunology.

[63]  M. Stanley,et al.  The host response to lesions induced by human papillomavirus. , 1994, Ciba Foundation symposium.

[64]  C. Meijer,et al.  HLA expression in pre-invasive cervical neoplasia in relation to human papilloma virus infection. , 1993, European journal of cancer.

[65]  L. Banks,et al.  The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. , 1992, Oncogene.

[66]  D. Pim,et al.  Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. , 1992, Oncogene.

[67]  A. Moscicki.  Human papillomavirus infections. , 1992, Advances in pediatrics.

[68]  P. Cresswell,et al.  Biosynthesis and processing of class II histocompatibility antigens. , 1987, Critical reviews in immunology.

[69]  D. Gawkrodger,et al.  Keratinocyte expression of MHC class II antigens in allergic sensitization and challenge reactions and in irritant contact dermatitis. , 1987, The Journal of investigative dermatology.